Eisai R&d Management Co., Ltd.

Megan Sheehan

Dominic J Reynolds

Andrew Cook

Sudeep Prajapati

Xiang Liu

James Palacino

Shelby Ellery

Thiwanka Samarakoon

Nathan Elliott Fishkin

Ping Zhu

Peter G Smith

Silvia Buonamici

Lihua Yu

Ermira Pazolli

Michael W Seiler

Zhenhua Wu

Nicholas Calandra

Yonghong Xiao

Shouyong Peng

Cheng Zhong

Jason T Lowe

Ryan Brawn

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Splicing modulator antibody-drug conjugates and methods of use

The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy

Certain aryl pladienolide compounds and methods of use

Growing community of inventors

Allston, MA, United States of America

Megan Sheehan